These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 313873)

  • 1. A trial of 5-fluorouracil and Corynebacterium parvum in advanced colorectal carcinoma.
    Gough IR; Clunie GJ; Bolton PM; Dury M; Burnett W
    Dis Colon Rectum; 1979; 22(4):223-7. PubMed ID: 313873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of Corynebacterium parvum on human effector cells in peripheral blood.
    Gill PG; Waller CA; Clarke J; Darley J; Morris PJ
    Dev Biol Stand; 1977 Apr 13-15; 38():455-60. PubMed ID: 608538
    [No Abstract]   [Full Text] [Related]  

  • 3. Chemoimmunotherapy in disseminated melanoma and colorectal carcinoma.
    Gough IR; Bolton PM; Clunie GJ; Burnett W
    Aust N Z J Surg; 1978 Jun; 48(3):296-300. PubMed ID: 281221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Initial experiences with a nation-wide Austrian study of adjuvant chemo- and immunotherapy of colorectal cancer following radical surgery].
    Karrer K; Denck H; Pridun N
    Acta Med Austriaca Suppl; 1979; 6():325-6. PubMed ID: 299221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value of immune monitoring in gynecologic cancer patients receiving immunotherapy.
    DiSaia PJ; Rich WM
    Am J Obstet Gynecol; 1979 Dec; 135(7):907-16. PubMed ID: 315714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous Corynebacterium parvum: an adjunct to chemotherapy for resistant advanced ovarian cancer.
    Rao B; Wanebo HJ; Ochoa M; Lewis JL; Oettgen HF
    Cancer; 1977 Feb; 39(2):514-26. PubMed ID: 837334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunological response in patients receiving Corynebacterium parvum therapy.
    Osborn DE; Castro JE
    Clin Oncol; 1977 Jun; 3(2):155-64. PubMed ID: 872468
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of intravenous corynebacterium parvum on peripheral-blood effector cells of cancer patients.
    Gill PG; Waller CA; MacClennan IC; Morris PJ
    Br J Cancer; 1980 May; 41(5):782-9. PubMed ID: 7426303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunologic evaluation of patients with advanced head and neck cancer receiving weekly chemoimmunotherapy.
    Zighelboim J; Dorey F; Parker NH; Calcaterra T; Ward P; Fahey JL
    Cancer; 1979 Jul; 44(1):117-23. PubMed ID: 313240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of repeated Corynebacterium parvum and BCG therapy on immune parameters: a weekly sequential study of melanoma patients. I. Changes in non-specific (NK, K and T cell) lymphocytotoxicity, peripheral blood counts and delayed hypersensitivity reactions.
    Thatcher N; Swindell R; Crowther D
    Clin Exp Immunol; 1979 May; 36(2):227-36. PubMed ID: 314367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of intravenous infusion of Corynebacterium parvum on an immune profile of women with breast cancer.
    Webster DJ; Chare MJ; Baum M
    Dev Biol Stand; 1977 Apr 13-15; 38():467-70. PubMed ID: 608540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of advanced ovarian malignancy with chemoimmunotherapy using autologous tumor and Corynebacterium parvum.
    Gusdon JP; Homesley HD; Jobson VW; Muss HB
    Obstet Gynecol; 1983 Dec; 62(6):728-35. PubMed ID: 6633998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of correlation of T and B lymphocytes with stage of colorectal carcinoma.
    Neilan BA
    Dis Colon Rectum; 1980 Mar; 23(2):65-7. PubMed ID: 6966563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunopotentiation of cell-mediated hypersensitivity by Corynebacterium parvum (Propionibacterium acnes).
    Maguire HC; Cipriano D
    Int Arch Allergy Appl Immunol; 1983; 70(1):34-9. PubMed ID: 6848475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daily intravenous infusions of Corynebacterium parvum in twenty patients with disseminated cancer: a preliminary report of clinical and biologic findings.
    Israël L; Edelstein R; Depierre A; Dimitrov N
    J Natl Cancer Inst; 1975 Jul; 55(1):29-33. PubMed ID: 1080521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant immunotherapy and chemoimmunotherapy in colorectal cancer (Dukes' class C): prolongation of disease-free interval and survival.
    Mavligit GM; Gutterman JU; Malahy MA; Burgess MA; McBride CM; Jubert A; Hersh EM
    Cancer; 1977 Nov; 40(5 Suppl):2726-30. PubMed ID: 922710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A trial of nonspecific immunotherapy using systemic C. parvum in treated patients with Dukes B and C colorectal cancer.
    Souter RG; Gill PG; Morris PJ
    Br J Cancer; 1982 Apr; 45(4):506-12. PubMed ID: 7041943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Corynebacterium parvum and BCG therapy on immune parameters in patients with disseminated melanoma. A sequential study over 28 days. II. Changes in non-specific (NK, K and T cell) lymphocytoxicity and delayed hypersensitivity skin reactions.
    Thatcher N; Swindell R; Crowther D
    Clin Exp Immunol; 1979 Feb; 35(2):171-9. PubMed ID: 312169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell-mediated immune status of colon cancer patients: evaluation by dermal antigen testing, measurment of lymphocyte stimulation and counts of peripheral blood rosette-forming cells.
    Evans JT; Goldrosen MH; Minowada J; Howell J; Mittelman A; Chu TM; Holyoke ED
    Cancer; 1977 Nov; 40(5 Suppl):2716-25. PubMed ID: 303541
    [No Abstract]   [Full Text] [Related]  

  • 20. The immunobiology of colorectal cancer.
    Mcdonald JS
    Semin Oncol; 1976 Dec; 3(4):421-31. PubMed ID: 793017
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.